Azaya Therapeutics, Inc. - Product Pipeline Review - Q1 2011

Azaya Therapeutics, Inc. – Product Pipeline Review – Q1 2011

Summary

Global Market Direct’s pharmaceuticals report, “Azaya Therapeutics, Inc. - Product Pipeline Review - Q1 2011” provides data on the company’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Azaya Therapeutics, Inc. - Brief company overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Azaya Therapeutics, Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Azaya Therapeutics, Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Azaya Therapeutics, Inc.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Azaya Therapeutics, Inc.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Azaya Therapeutics, Inc. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Azaya Therapeutics, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Azaya Therapeutics, Inc..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Azaya Therapeutics, Inc. and identify potential opportunities in those areas. SHOW LESS READ MORE >

List of Tables
List of Figures
Azaya Therapeutics, Inc. Snapshot
Azaya Therapeutics, Inc. Overview
Key Information
Key Facts
Azaya Therapeutics, Inc. – Research and Development Overview
Key Therapeutic Areas
Azaya Therapeutics, Inc. – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Azaya Therapeutics, Inc. – Pipeline Products Glance
Azaya Therapeutics, Inc. Clinical Stage Pipeline Products
Phase I Products/Combination Treatment Modalities
Azaya Therapeutics, Inc.–Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Discovery Products/Combination Treatment Modalities
Azaya Therapeutics, Inc. – Drug Profiles
ATI-1123
Product Description
Mechanism of Action
R&D Progress
ATI-1025
Product Description
Mechanism of Action
R&D Progress
ATI-1123
Product Description
Mechanism of Action
R&D Progress
ATI-1150
Product Description
Mechanism of Action
R&D Progress
ATI-0107
Product Description
Mechanism of Action
R&D Progress
ATI-0506
Product Description
Mechanism of Action
R&D Progress
ATI-0721
Product Description
Mechanism of Action
R&D Progress
ATI-0909
Product Description
Mechanism of Action
R&D Progress
ATI-0918
Product Description
Mechanism of Action
R&D Progress
ATI-1110
Product Description
Mechanism of Action
R&D Progress
ATI-1113
Product Description
Mechanism of Action
R&D Progress
ATI-1220
Product Description
Mechanism of Action
R&D Progress
Azaya Therapeutics, Inc. – Pipeline Analysis
Azaya Therapeutics, Inc. – Pipeline Products by Therapeutic Class
Azaya Therapeutics, Inc. - Pipeline Products By Target
Azaya Therapeutics, Inc. – Pipeline Products by Route of Administration
Azaya Therapeutics, Inc. – Pipeline Products by Molecule Type
Azaya Therapeutics, Inc. – Locations And Subsidiaries
Head Office
Recent Developments
Jan 26, 2010: ResearchPoint & Azaya Therapeutics Enroll First Patient in Phase I Clinical Study
Jan 26, 2010: ResearchPoint & Azaya Therapeutics Enroll First Patient in Phase I Clinical Study
Financial Deals Landscape
Azaya Therapeutics, Inc., Deals Summary, 2004 to 2011
Azaya Therapeutics, Inc. Detailed Deal Summary
Licensing Agreements
Azaya Therapeutics Enters Into Licensing Agreement With The University of Texas Health Science Center at San Antonio
]

Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Azaya Therapeutics, Inc. – Pipeline by Therapy Area and Indication, 2011
Azaya Therapeutics, Inc. – Pipeline by Stage of Development, 2011
Azaya Therapeutics, Inc. – Monotherapy Products in Pipeline, 2011
Azaya Therapeutics, Inc. - Phase I, 2011
Azaya Therapeutics, Inc. - Pipeline By Therapeutic Class, 2011
Azaya Therapeutics, Inc. - Pipeline By Target, 2011
Azaya Therapeutics, Inc. – Pipeline By Route of Administration, 2011
Azaya Therapeutics, Inc. – Pipeline By Molecule Type, 2011
Azaya Therapeutics, Inc., Deals Summary, 2004 to 2011

List of Figures
Azaya Therapeutics, Inc. – Pipeline by Therapy Area and Indication, 2011
Azaya Therapeutics, Inc. – Pipeline by Stage of Development, 2011
Azaya Therapeutics, Inc. – Monotherapy Products in Pipeline, 2011
Azaya Therapeutics, Inc. - Pipeline By Target, 2011
Azaya Therapeutics, Inc. – Pipeline By Molecule Type, 2011